Literature DB >> 21360263

Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells.

Jin Ku Kang1, Chang-Hyun Chang, Hyo Jung Nam, Sung-Kuk Kim, Keun Jae Ahn, Heon Seok, Sang Joon Park, Yoon Joong Kang, Young Suk Jo, Minho Shong, Ho Kim.   

Abstract

BACKGROUND: Phospholipase C-γl (PLC-γl) is known to play a critical role in cell adhesion and migration and is highly expressed in metastatic tumors. In the current study, we found that cells transformed by PLC overexpression (PLC-γl cells) exhibited a marked decrease in expression of the Epo receptor (EpoR). Here, we assessed the role of EpoR-dependent signaling pathways in PLC-γl-dependent regulation of cell adhesion and migration.
METHODS: Expression and phosphorylation of EpoR and its functional role in PLC-γl cells were evaluated by immunoblot analysis or cell adhesion assay. The mechanism for PLC-γ1-induced EpoR downregulation was analyzed by blockage of proteosomal degradation with MG132. EpoR expression was also confirmed in colorectal cancer tissues in which PLC-γl was highly expressed.
RESULTS: EpoR was present on rat fibroblasts, where it functionally active and capable of increasing cell adhesion and migratory activity. However, PLC-γl cells significantly decreased the Epo-dependent effects via ubiquitination-proteosomal degradation of EpoR. A marked decrease of EpoR expression was confirmed in colorectal cancer tissues that showed high-level of PLC-γl expression.
CONCLUSION: The Epo/EpoR complex plays a critical role in the adhesion and migration of rat fibroblasts, and its functional inactivation is associated with PLC-γl-dependent reduction of cell-matrix adhesion and this also affects cell migration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360263     DOI: 10.1007/s13402-010-0001-9

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  42 in total

1.  Breast cancer trial with erythropoietin terminated unexpectedly.

Authors:  Brian Leyland-Jones
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

2.  Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system.

Authors:  H Nakayama; H Yokoi; J Fujita
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

Review 3.  Erythropoietin biology in cancer.

Authors:  Matthew E Hardee; Murat O Arcasoy; Kimberly L Blackwell; John P Kirkpatrick; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

4.  Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema.

Authors:  Weiye Li; Stephen H Sinclair; Guo-Tong Xu
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2010 Jan-Feb

5.  Overexpression of phospholipase C-gamma 1 in familial adenomatous polyposis.

Authors:  J G Park; Y H Lee; S S Kim; K J Park; D Y Noh; S H Ryu; P G Suh
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

6.  Phospholipase C-gamma1 potentiates integrin-dependent cell spreading and migration through Pyk2/paxillin activation.

Authors:  Jang Hyun Choi; Yong-Ryoul Yang; Seul Ki Lee; Il-Shin Kim; Sang Hoon Ha; Eung-Kyun Kim; Yun Soo Bae; Sung Ho Ryu; Pann-Ghill Suh
Journal:  Cell Signal       Date:  2007-04-19       Impact factor: 4.315

7.  Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells.

Authors:  M J Koury; M C Bondurant
Journal:  J Cell Physiol       Date:  1988-10       Impact factor: 6.384

8.  Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes.

Authors:  D Neumann; L Wikström; S S Watowich; H F Lodish
Journal:  J Biol Chem       Date:  1993-06-25       Impact factor: 5.157

9.  Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.

Authors:  A M Sinclair; N Rogers; L Busse; I Archibeque; W Brown; P D Kassner; J E V Watson; G E Arnold; K C Q Nguyen; S Powers; S Elliott
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

10.  Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways.

Authors:  Remond J A Fijneman; Lindsey K Bade; Johannes R Peham; Mark A van de Wiel; Victor W M van Hinsbergh; Gerrit A Meijer; Michael G O'Sullivan; Robert T Cormier
Journal:  Cell Oncol       Date:  2009       Impact factor: 6.730

View more
  5 in total

1.  Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers.

Authors:  Chien-Rui Lai; Hisao-Hsien Wang; Hsin-Han Chang; Yu-Ling Tsai; Wen-Chiuan Tsai; Chen-Ray Lee; Chih-Ying Changchien; Yu-Chen Cheng; Sheng-Tang Wu; Ying Chen
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

Review 2.  Progress in detecting cell-surface protein receptors: the erythropoietin receptor example.

Authors:  Steve Elliott; Angus Sinclair; Helen Collins; Linda Rice; Wolfgang Jelkmann
Journal:  Ann Hematol       Date:  2013-12-14       Impact factor: 3.673

3.  Phospholipase Cγ1 links inflammation and tumorigenesis in colitis-associated cancer.

Authors:  Kwang-Il Park; Kwang-Youn Kim; Tae Woo Oh; Du-Seock Kang; Eung-Kyun Kim; Yong Ryoul Yang; Young-Kyo Seo; Jin-Yeul Ma; Pann-Ghill Suh
Journal:  Oncotarget       Date:  2017-12-19

4.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

5.  Epo receptors are not detectable in primary human tumor tissue samples.

Authors:  Steve Elliott; Susan Swift; Leigh Busse; Sheila Scully; Gwyneth Van; John Rossi; Carol Johnson
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.